real-time news and commentary for investors
Friday, Aug 30
Edoxaban poses limited threat to Bristol-Myers' Eliquis: Goldman
- Shares of Bristol-Myers Squibb (BMY -0.2%) will be worth watching come Monday as data on Daiichi Sankyo's edoxaban is set to be presented this weekend at the annual meeting of the European Society of Cardiology.
- Some say the drug presents a risk to BMY's Eliquis.
- Goldman's Jami Rubin thinks "BMY's long-term growth prospects are dependent upon PD-1 and not Eliquis, particularly as Eliquis estimates have been substantially reduced."